Results 131 to 140 of about 4,101 (234)

Pseudo-Richter Transformation Following BTKi Interruption in CLL: A Systematic Review of Clinical, Biological, and Pathologic Features [PDF]

Javier Marco-Ayala, M Dolores García Malo, Francisco José Ortuño, ML Lozano   +3 more
openalex   +1 more source

P122 | ULTRASOUND ASSESSMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH BTK INHIBITORS. CLINICAL AND PHARMACOECONOMIC IMPACT

Haematologica
Background. IWCC and ESMO guidelines (I&EGu) suggest abdominal ultrasound (US) and superficial lymphnodes (SLN) palpation to assess patients with chronic lymphocytic leukemia (CLL) in general practice.
E. Benedetti, M.C. Caparello, B. Bruno, S. Galimberti, E. Bramanti, R. Morganti   +5 more
doaj  

Phase I/II, first in human trial with M7583, a Bruton’s tyrosine kinase inhibitor (BTKi), in patients with B cell malignancies

, 2018
Wojciech Jurczak, Simon Rule, William Townsend, David Tucker, Barbara Sarholz, J. Scheele, John G. Gribben, Pier Luigi Zinzani   +7 more
openalex   +1 more source

CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL

, 2022
Emily Bryer, Shira Paul, Jonathan Chen, Christopher Pleyer, Adrian Wiestner, Clare Sun   +5 more
openalex   +2 more sources

Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström macroglobulinemia: a real-life multicenter Italian study. [PDF]

Blood Adv
Autore F, Tedeschi A, Benevolo G, Danesin N, Giannarelli D, Rizzi R, Cencini E, Mattiello V, Ferrarini I, Pasquale R, Del Giudice I, Ferrari A, Bullo M, Rossini B, Motta M, Marino D, Innocenti I, Stirparo L, Petrilli D, Musto P, Peri V, Zamprogna G, Hohaus S, Frustaci AM, Piazza F, Ferrero S, Laurenti L.   +26 more
europepmc   +1 more source

Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia

, 2023
Scott F. Huntington, Beenish S. Manzoor, Justin Puckett, Sachin Kamal‐Bahl, Hasan Alhasani, Arliene Ravelo, Dureshahwar Jawaid, Jalpa A. Doshi   +7 more
openalex   +1 more source

Bruton's tyrosine kinase inhibitors in diffuse large B-cell lymphoma therapy: critical considerations and future innovations. [PDF]

J Transl Med
Lu C, Chen Q, Shen Y, Chen M, Xie Y, Wang C, Yu L.   +6 more
europepmc   +1 more source

REAL-WORLD (RW) CHARACTERISTICS, TREATMENT PATTERNS, AND ECONOMIC IMPACT OF PATIENTS TREATED WITH BRUTON`S TYROSINE KINASE INHIBITORS (BTKI) IN A LARGE PRIVATE BRAZILIAN HEALTHCARE PROVIDER.

V.K. Gonçalves, S Stefani, H Reschke
openalex   +1 more source

Real-world comparison of BTK inhibitors and lenalidomide as first-line maintenance in primary CNS lymphoma: a multi-center retrospective study. [PDF]

J Neurooncol
Chang X, He Z, Wang H, Zhu H, Guo Y, Zou D, Zhao Z, Song T, Hu R, Ni J, Zhao H, Hui W, Liu Z, Li Z, Zhang W, Zhou D, Zhang Y, Sun W.   +17 more
europepmc   +1 more source

Effects of Btk-inhibitors with varying selectivity and reversibility on platelet aggregation [PDF]

, 2022
Duan, Rundan
core